ACER - Acer Therapeutics Inc Stock Price, Fair Value and News

$0.66

Market Closed

ACER Stock Valuation Analysis

Valuation

Max Portfolio %

ACER Price Action

ACER RSI Chart

ACER Stock Valuation Analysis

Valuation

Max Portfolio %

ACER Valuation

ACER Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ACER Fundamentals

ACER Revenue

ACER Earnings

ACER Profitability

ACER Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	731.8K	0
2021	3.1M	2.4M	1.6M	1.3M
2016	2.9M	2.9M	2.9M	2.9M
2015	1.3M	1.7M	2.1M	2.6M
2014	1.4M	1.4M	1.3M	1.3M
2013	0	0	0	1.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Acer Therapeutics Inc

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.

CEO	Mr. Christopher Schelling
WEBSITE	acertx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	30